Skip to main content
Back to News
Ataraxis AI, backed by $20.4 M Series A and $24 M total funding, is launching a 2026 Clinical Strate...
Expansion
1 min read
US

Ataraxis AI, backed by $20.4 M Series A and $24 M total funding, is launching a 2026 Clinical Strate...

The AMW Read

The article provides an incremental update on Ataraxis AI's scaling through new talent acquisition and headcount expansion in the oncology vertical.
NoveltySignificance
Healthcare & Bio · Player Map

Ataraxis AI, backed by $20.4 M Series A and $24 M total funding, is launching a 2026 Clinical Strategy Internship at its New York HQ. The role will let interns shape AI‑driven oncology strategies as the company pushes toward its goal of impacting 50 % of new cancer cases by 2030. This talent boost signals rapid scaling of AI‑native precision medicine tools like the Ataraxis™ Breast platform. 🚀

#AI #PrecisionMedicine #Oncology #HealthTech #Internship

How This Connects

Based on Healthcare & Bio · Player Map

  1. 4d agoIsomorphic Labs raises $5 billion Series C for AI drug discoveryIsomorphic Labs
  2. 0mo agoPathos AI raises $237M to scale Foundry and advance four oncology assetsPathos
  3. 0mo agoWarp Sciences, founded by former OpenAI science lead Kevin Weil, raises $215M to automate drug-chemistry labsWarp Sciences
  4. 7mo agoAtaraxis AI, backed by $20.4 M Series A and $24 M total funding, is launching a 2026 Clinical Strate... · THIS ARTICLE

More news from Ataraxis AI

Stay updated with the latest news and announcements from Ataraxis AI.

View all Ataraxis AI news

Discover AI Startups

Explore 5,000+ AI companies with VC-grade analysis, funding data, and investment insights.

Explore Dashboard